AARD - Aardvark Therapeutics, Inc.


7.02
-0.770   -10.969%

Share volume: 65,445
Last Updated: 04-10-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.01%

PREVIOUS CLOSE
CHG
CHG%

$7.79
-0.77
-0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-11.59%
1 Month
-32.63%
3 Months
-50.94%
6 Months
-50.94%
1 Year
-50.94%
2 Year
-50.94%
Key data
Stock price
$7.02
P/E Ratio 
N/A
DAY RANGE
$6.51 - $7.82
EPS 
N/A
52 WEEK RANGE
$4.88 - $19.58
52 WEEK CHANGE
-$50.94
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$185,272
AVERAGE 30 VOLUME 
$147,271
Company detail
CEO: Tien-Li Lee
Region: US
Website: aardvarktherapeutics.com
Employees: 18
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We were incorporated in Delaware on May 17, 2017. Our principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA. We have one wholly-owned subsidiary, Artisan Therapeutics, Inc., incorporated in Delaware in October 2024.

Recent news
loading